Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal–bolus treatment in people with Type 1 diabetes: 1–year results from a randomized clinical trial (BOOST (®) T1)

AIMS: To evaluate the long‐term safety and efficacy of a simplified basal–bolus regimen of once‐daily insulin degludec/insulin aspart (IDegAsp) with additional IAsp vs. a standard basal–bolus insulin regimen of insulin detemir (IDet) with IAsp in adults with Type 1 diabetes. METHODS: This was an ope...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirsch, I. B., Franek, E., Mersebach, H., Bardtrum, L., Hermansen, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5248618/
https://www.ncbi.nlm.nih.gov/pubmed/26773446
http://dx.doi.org/10.1111/dme.13068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5248618/
https://www.ncbi.nlm.nih.gov/pubmed/26773446
http://dx.doi.org/10.1111/dme.13068

Ejemplares similares